Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2024-01-25 , DOI: 10.1080/14737167.2023.2263166
Sharon Wolters _{1,

2} , Lisa A de Jong ₂ , Christel Jansen _{3,

4} , Frank Ga Jansman _{5,

6} , Maarten J Postma _{2,

7,

8}

Affiliation

Evidentiary requirements for relative effectiveness assessment vary among European health technology assessment (HTA) bodies, affecting the time to HTA decision-making and potentially delaying time...

中文翻译：